Background: Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited. Objectives: To systematically evaluate the efficacy and safety of IncobotulinumtoxinA compared with placebo for the simultaneous treatment of UFLs in adults, following PRISMA 2020 guidelines. Methods: Comprehensive searches of PubMed, Embase, Cochrane CENTRAL, ICTRP, and ClinicalTrials.gov were performed to identify randomized controlled trials (RCTs) evaluating IncobotulinumtoxinA for combined UFLs treatment. The primary outcome was ≥1-grade improvement on Day 30. Secondary outcomes included ≥2-grade improvement and Global Aesthetic Improvement Scale (GAIS) scores. Safety outcomes included adverse events (AEs), treatment-emergent adverse events (TEAEs), and headaches. Results: Three RCTs (n = 704) were included. Pooled analysis using random-effects model demonstrated a significant ≥1-grade improvement at Day 30 in IncobotulinumtoxinA compared with placebo across all regions: GFLs (RR 21.49, 95% CI: 9.89-46.73), HFLs (RR 19.17, 95% CI: 9.23-39.80), and LCLs (RR 11.68, 95% CI: 7.49-18.20), all P < .00001. A ≥ 2-grade improvement similarly favored treatment across all areas (RRs 76.26-115.04; all P < .00001). Investigator-assessed GAIS scores also improved significantly (MD 2.29, 95% CI: 2.11-2.46, P < .00001). Serious AEs were lower with IncobotulinumtoxinA (RR 0.14, P = .03). There was no significant difference in TEAEs and headaches from placebo. Conclusions: IncobotulinumtoxinA demonstrates statistically significant efficacy and a comparable safety profile vs placebo for simultaneous UFLs treatment. These findings support its use in aesthetic practice, warranting further long-term investigation. Level of Evidence: 1 (Therapeutic): For image description, please refer to the figure legend and surrounding text.